Shares of Biogen  (BIIB) - Get Report were climbing Monday after the drug maker received a rare double upgrade from analysts at Morgan Stanley who now have an overweight rating on the stock.Morgan Stanley analyst Matthew Harrison still sees near-term downside risks from generic competitors to Biogen's Tecfidera multiple sclerosis treatment, but there is upside in the company's experimental Alzherimer's treatment, aducanumab.